Oura is rolling out two new women’s health tools on May 6: Menopause Insights, which uses a clinical questionnaire to assess symptoms and track quality-of-life impact, and Hormonal Birth Control, linking contraceptive methods with biometric data to show effects on sleep, temperature, and cycles.

The company is expanding care delivery through a U.S. partnership with Twentyeight Health, enabling same-day virtual appointments, prescriptions, and ongoing contraceptive counseling, with cycle and sleep data integrated to personalize care.

After assessments, users receive a personalized dashboard showing overall impact level and contributing factors, with results that can be saved and shared with healthcare providers to support clinical discussions.

Six months into using the Oura Ring 4 Ceramic, the author remains highly satisfied, citing durability and a flawless ceramic finish despite heavy daily wear.

The updates are positioned as differentiators that reinforce Oura’s premium status and value, even with higher cost and ongoing subscription.

Market context notes continued competition from Ultrahuman and RingConn, with new rings in development, but Oura's leadership and ecosystem innovation keep it hard to beat for now.

Information comes from Oura’s official announcement and a Yugatech article, with clear notes on rollout timing and device compatibility.

Battery life remains strong, lasting at least five days per charge, with a low-battery alert when less than a day remains.

Rollout begins globally on May 6, 2026, with Gen3 and Ring 4 Members eligible, and Oura Ring 4 highlighted for wearables enthusiasts.

The update rollout is global and described as a first-of-its-kind experience within Oura’s app, currently available to Ring Series 3 and 4 users.

Meanwhile, Maven and Progyny are partnering with Oura to integrate ring-derived insights into clinical workflows and care plans.

Users can track changes over time, compare with biometric data, export data, and share with healthcare providers to inform treatment and care decisions.